Monitoring Methotrexate-induced Increased Liver Stiffness and Significant Liver Fibrosis in Rheumatoid Arthritis Patients: A Cross-sectional Controlled Study with Real-time Two-dimensional Shear Wave Elastography
Citation Information :
Chattopadhyay D, Das S, Gantait K. Monitoring Methotrexate-induced Increased Liver Stiffness and Significant Liver Fibrosis in Rheumatoid Arthritis Patients: A Cross-sectional Controlled Study with Real-time Two-dimensional Shear Wave Elastography. Bengal Physician Journal 2023; 10 (2):43-46.
Objective: To explore the significance of the association between treatment with methotrexate (MTX) and liver stiffness in rheumatoid arthritis (RA) patients by transient elastography (TM).
Methodology: In this cross-sectional study, a total of 100 adult patients of RA were selected randomly as the study population, and 50 were the control population. Out of the total study population, half of them were taking MTX for >2 years to 5 years, and the rest for >5 years. Hepatic fibrosis was determined by measuring the hepatic stiffness by TE method (by FibroScan) in kilopascal unit (kPa), where >9 kPa value was considered to be significant for developing hepatic fibrosis. The hepatic stiffness of the patient group was compared with that of healthy controls.
Result: The mean BMI value between the two groups taking methotrexate therapy for < 5 years and >5 years was 22.37 ± 2.67 kg/m2 and 25.13 ± 3.09 kg/m2, and the control population was 20.71 ± 2.06 kg/m2. P-value came to be < 0.0001, which was statistically significant, and the effect of mean BMI on liver stiffness was also found significant (p = 0.04). The mean (mean ± SD) kPa value among the study population and control group is 6.04 ± 0.95, 6.67 ± 1.68, and 3.83 ± 0.52. Having compared among three groups, p-value was < 0.0001. A significant association was also found regarding the duration of MTX therapy with increased liver stiffness (p = 0.018). SDAI has been found to be positively correlated with increased hepatic stiffness (r = 0.077).
Conclusion: The long-term use of methotrexate therapy in RA patients has been found to be significantly associated with progressive liver fibrosis and increased hepatic stiffness.
Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76(6):960–977. DOI: 10.1136/annrheumdis- 2016-210715.
Lertnawapan R, Chonprasertsuk S, Siramolpiwat S. Association between cumulative methotrexate dose, noninvasive scoring system and hepatic fibrosis detected by Fibroscan in rheumatoid arthritis patients receiving methotrexate. Int J Rheum Dis 2019;22(2):214–221. DOI: 10.1111/1756-185X.13442.
Mangoni AA, Zinellu A, Sotgia S, et al. Protective effects of methotrexate against proatherosclerotic cytokines: A review of the evidence. Mediators Inflamm 2017;2017:9632846. DOI: 10.1155/2017/9632846.
Kremer JM, Alarcòn GS, Lightfoot RW, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994;37(3):316–328. DOI: 10.1002/art.1780370304.
Whiting-O'Keefe QE, Fye KH, Sack KD, et al. Methotrexate and histologic hepatic abnormalities: A meta-analysis. Am J Med 1991;90(6):711–716. PMID: 1828327.
Herrmann E, de Lédinghen V, Cassinotto C, et al. Assessment of biopsy proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data based metaanalysis. Hepatology 2018;67(1):260–272. DOI: 10.1002/hep.29179.
Kim TY, Kim JY, Sohn JH, et al. Assessment of substantial liver fibrosis by real time shear wave elastography in methotrexate treated patients with rheumatoid arthritis. J Ultrasound Med 2015;34(9): 1621–1630. DOI: 10.7863/ultra.15.14.10035.
Kremer JM, Kaye GI, Kaye NW, et al. MTX for RA. Light and electron microscopic analysis of sequential liver biopsy samples from RA patients receiving long-term MTX therapy. FU over long-term interval and correlation of clinical and laboratory variables. Arthritis Rheum 1995;38(9):1194–1203. DOI: 10.1002/art.1780380904.
Conway R, Low C, Coughlan RJ, et al. Risk of liver injury among MTX users: A meta-analysis of RCT. Semin Arthritis Rheum 2015;45(2): 156–162. DOI: 10.1016/j.semarthrit.2015.05.003.
Visser K. Risk and management of liver toxicity in Ra & PsA: Systemic review of the literature. Clin Exp Rheumatol 2009;27(6):1017–1025. PMID: 20149325.
Kumar A, Vasdev V, Manrai M, et al. Assessment of hepatic fibrosis in patients with rheumatoid arthritis on long-term methotrexate therapy using transient elastography. J Indian J Rheumatol Assoc 2018;13(4):246–251. DOI: 10.4103/injr.injr_92_18.